CCR Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The NCI Center for Cancer Research (CCR) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 11 clinical trials at NIH that match your search criteria

Cancer by type/disease: Prostate Cancer

Trial and Protocol Number Prostate Cancer	Principal Investigator	Referral Contact
Pilot
A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer NCI-09-C-0139	Jay A. Berzofsky 301-496-6874	Brenda Roberson 301-435-4733 broberson@mail.nih.gov
Phase II
A Phase II Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) NCI-09-C-0195	William L. Dahut 301-435-8183	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase II Study of Satraplatin and Prednisone in Metastatic Androgen-Independent Prostate Cancer (APIC) NCI-08-C-0074	William L. Dahut 301-435-8183	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men With Androgen Insensitive, Non-Metastatic (D0.5) Prostate Cancer NCI-07-C-0107	James L. Gulley 301-435-2956	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Randomized Phase 2.5 Study of [153]Sm-EDTMP (Quadramet) With or Without a PSA TRICOM Vaccine in Men With Androgen-Insensitive Metastatic Prostate Cancer NCI-07-C-0106	James L. Gulley 301-435-2956	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase II Study of AZD2171 in Metastatic Androgen-Independent Prostate Cancer NCI-07-C-0059	William L. Dahut 301-435-8183	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase II Study of Docetaxel, Thalidomide, Prednisone, and Bevacizumab in Patients With Metastatic Androgen-Independent Prostate Cancer NCI-04-C-0257	William L. Dahut 301-435-8183	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
Phase I
A Pilot Study of Image Guided Prostate and Pelvic Nodal Irradiation With Intensity Modulated Radiation Therapy (IMRT) NCI-05-C-0241	Aradhana Kaushal 301-496-5457	Deborah McNally 301-496-5457 cooleyd@navmed.nci.nih.gov
A Phase I Study of Image Guided Dose Escalation With Intensity Modulated Radiation Therapy (IMRT) to Histologically Confirmed Regions of Prostate Cancer NCI-05-C-0191	Aradhana Kaushal 301-496-5457	Deborah McNally 301-496-5457 cooleyd@navmed.nci.nih.gov

Trial and Protocol Number Solid Tumor	Principal Investigator	Referral Contact
Phase I
A Phase I, Open-Label Study of MEDI-547 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biologic Activity of Intravenous Administration in Subjects With Refractory Solid Tumors Associated With EphA2 Expression NCI-09-C-0168	Elise C. Kohn 301-402-2726	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
No Phase
A Natural History Study of Patients Receiving High Dose Rate Brachytherapy NCI-09-C-0100	Aradhana Kaushal 301-496-5457	Sharon L. Smith 301-496-5457 smiths@mail.nih.gov

For additional studies that may be appropriate for your disease type, please search under Solid Tumor.